TRAX (First Tracks Biotherapeutics, Inc. Ordinary Shares) Stock Analysis - Insider Trades

First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) is a publicly traded the market company. As of May 21, 2026, TRAX trades at $16.74 with a market cap of $620.74M and a P/E ratio of 0.00. TRAX moved -2.16% today. Year to date, TRAX is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $14.79 to $25.58. Analyst consensus is strong buy with an average price target of $38.50. Rallies surfaces TRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TRAX stock inside the company?

Recent TRAX insider activity includes EcoR1 Capital, LLC bought 4.71M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TRAX Key Metrics

Key financial metrics for TRAX
MetricValue
Price$16.74
Market Cap$620.74M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$25.58
52-Week Low$14.79
Volume75
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Recent TRAX Insider Trades

  • EcoR1 Capital, LLC bought 4.71M (~$65.00M) on Apr 20, 2026.

Latest TRAX News

TRAX Analyst Consensus

6 analysts cover TRAX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.50.

Common questions about TRAX

Who is trading TRAX stock inside the company?
Recent TRAX insider activity includes EcoR1 Capital, LLC bought 4.71M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TRAX?
Yes. Rallies tracks TRAX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TRAX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TRAX. It does not provide personalized investment advice.
TRAX

TRAX